Defence Therapeutics Inc.
DTCFF
$0.39
$0.0411.57%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -58.73% | -10.93% | 67.17% | 71.87% | 71.24% |
| Total Depreciation and Amortization | -46.67% | -42.62% | -27.88% | -22.31% | 130.41% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 88.32% | 83.12% | -79.34% | -79.20% | -80.17% |
| Change in Net Operating Assets | -47.45% | -226.59% | -167.55% | -135.21% | -123.76% |
| Cash from Operations | -48.90% | -134.18% | -45.89% | 24.34% | 49.95% |
| Capital Expenditure | -188.71% | 92.47% | 89.53% | -- | 107.43% |
| Sale of Property, Plant, and Equipment | -181.20% | -181.20% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -184.82% | 83.58% | 91.24% | 101.66% | 115.39% |
| Total Debt Issued | 2,976.92% | 2,976.92% | 2,976.92% | -70.00% | -- |
| Total Debt Repaid | 90.19% | 76.34% | -366.85% | -682.48% | -1,895.74% |
| Issuance of Common Stock | -27.98% | 87.28% | 165.44% | 165.44% | 23.93% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 37.65% | -184.25% | -171.19% | -71.56% | 4.82% |
| Cash from Financing | 20.87% | 177.23% | 248.43% | 146.09% | 16.02% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -41.09% | 445.92% | 271.93% | 139.53% | 161.51% |